
|Videos|August 22, 2022
Dr. Packiam on background of study of sequential intravesical chemo in BCG-naïve NMIBC
Author(s)Urology Times staff
Advertisement
Vignesh Packiam, MD, explains the background of the study, “Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer,” which was published in the Journal of Urology. Packiam is a clinical assistant professor of Urology, Department of Urology, University of Iowa Hospitals and Clinics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
ARASEC: Clinical Implications and the Role of Multidisciplinary Care
2
FDA grants tentative approval to generic enzalutamide tablets
3
2026 AUA/SUO Advanced Prostate Cancer Guideline: Key updates and clinical FAQs
4
Atish Choudhury, MD, PhD, highlights phase 2 data on treatment interruption in mHSPC
5













